INTRODUCTION

Metastasis to the thyroid gland (TM) is uncommon, accounting for approximately 1.4% to 3% of all thyroid malignancies[1]. It was reported that metastases mostly arise from the lung (21.8%), followed by the gastrointestinal tract (18.2%), breast (14.5%),and kidney (12.7%), in a recent Chinese study[2]. Patients with TM usually present with symptoms of thyroid nodules, thyroiditis or neck swelling, dysphagia,dysphonia, and cough[3]. Diffuse goiter without thyroid nodules is rarely seen as the first manifestation of TM. Skip metastases (SMs) of breast cancer to the lymph nodes,defined as discontiguous higher-level lymphadenopathy in the absence of lower levels of contiguous lymphadenopathy, have rarely been reported. Chung[4] reported that SMs occurred in 2.6% of 1300 newly diagnosed invasive breast cancers, and only 6% of these SMs occurred in the contralateral lymph nodes. Here, we report a rare case of TM first presenting as rapidly occurring diffuse goiter without thyroid nodules associated with SMs to the contralateral cervical lymph nodes in a primary breast cancer patient.

此次用戶大會期間，COMSOL在電池領(lǐng)域的一位用戶代表就為大家分享了他們的一些應(yīng)用經(jīng)驗(yàn)。據(jù)介紹，借助COMSOL多物理場仿真技術(shù)，該公司將仿真與試驗(yàn)相結(jié)合，建立了鋰離子動力電池設(shè)計(jì)也性能關(guān)系模型，幫助工程師了解電池設(shè)計(jì)中的限制因素，研究電池內(nèi)部反應(yīng)機(jī)制，指導(dǎo)電池設(shè)計(jì)參數(shù)的優(yōu)化，實(shí)現(xiàn)了提高產(chǎn)品質(zhì)量、縮短研發(fā)周期、降低成本的多方面目標(biāo)。

CASE PRESENTATION

Chief complaints

Grade C (Good): C

智慧校園擬采用服務(wù)器虛擬化和桌面虛擬化技術(shù)。服務(wù)器虛擬化是把服務(wù)器物理資源（如CPU、內(nèi)存、磁盤、I/O等）抽象成一個可以動態(tài)管理的邏輯資源池，把單臺物理服務(wù)器變成多臺邏輯上相互隔離的虛擬服務(wù)器，實(shí)現(xiàn)資源按需分配，提高服務(wù)器資源的利用率，簡化服務(wù)器的管理，實(shí)現(xiàn)服務(wù)器整合。不僅能降低電力和冷卻能耗，節(jié)省物理空間和成本，而且能提高基礎(chǔ)架構(gòu)的利用率，提高系統(tǒng)穩(wěn)定性，減少宕機(jī)事件的發(fā)生。高校計(jì)算機(jī)機(jī)房使用的微機(jī)，報(bào)廢周期一般是5～8年。有些微機(jī)并沒有物理上的損壞，只是運(yùn)行速度變慢，CPU和內(nèi)存不能滿足現(xiàn)行軟件的運(yùn)行而被淘汰，導(dǎo)致計(jì)算能力的巨大浪費(fèi)。

History of present illness

A 49-year-old Chinese woman was diagnosed with invasive ductal carcinoma (IDC) of the right breast with a chief complaint of palpable masses and right nipple discharge in October 2015 (Figure 1). The right axillary lymph nodes were also found to contain poorly differentiated metastatic breast carcinoma cells by fine-needle aspiration cytology (FNAC). No mass or enlarged lymph nodes were seen on the left side upon computed tomography (CT) scan or by ultrasound. The patient underwent preoperative neoadjuvant chemotherapy, with 3 cycles of the FEC (5-fluorouracil +epirubicin + cyclophosphamide) regimen and 3 cycles of the TG (vinorelbine +cisplatin) regimen (Figure 1). She was evaluated as having achieved partial remission after finishing chemotherapy. Subsequently, bilateral mastectomy was performed at the request of the patient in April 2016 (Figure 1). Surgical specimens showed T2N3(12/27) M0 grade 3 IDC with ductal carcinoma in situ on the right side based on hematoxylin and eosin (HE) staining and immunohistochemistry (IHC). Right axillary and intercostal lymph node metastases were also observed microscopically. No carcinoma was found in the left breast or axillary lymph nodes. IHC staining suggested estrogen receptor (ER, strong positive), progesterone receptor (PR,moderate positive) and human epidermal growth factor receptor 2 (HER-2, 2+)positivity, and the monoclonal antibody Ki-67 index was 60%. After surgery, the patient received endocrine therapy with anastrozole and goserelin. Radiation therapy was administered in 25 fractions to the right breast.

The IHC profiles of the patient changed during the process of cancer management.The immunostaining profiles of the core-tissue needle biopsy before NAC were ER(+++), PR (+++) and HER-2 (-), which changed to ER (+++), PR (++) and HER-2 (2+) in the surgical pathology results; finally, the cytology of enlarged lymph nodes and thyroid indicated triple negative breast cancer. Several studies have demonstrated that hormone receptor (ER and PR) status changes between initial core-tissue needle biopsy and surgical specimens obtained after chemotherapy and endocrine treatment. Tacca[38] reported that the positivity rate of HER-2 decreased from 42.0% to 32.1% after neoadjuvant chemotherapy, which could explain the conversion of HER-2 status between FNAC and surgery pathology results. A Chinese nationwide multicenter study showed that 37.7% of breast cancer patients have hormone receptor conversion in metastatic lesions, and patients with PR conversion had shorter overall survival times than patients whose PR remained positive (= 0.016)[39]. This reveals that IHC profiles may change in the process of metastasis, which offers more information for making precise individual treatment decisions.

所以，要想擁抱廣闊的農(nóng)村市場，就要學(xué)會研究和開發(fā)農(nóng)村市場。企業(yè)和生產(chǎn)經(jīng)營者要針對農(nóng)村地域遼闊，東西南北中農(nóng)村因地域差別、經(jīng)濟(jì)差別、生活習(xí)性差別，而呈現(xiàn)消費(fèi)者需求的多層性和多樣性，消費(fèi)方向各有特點(diǎn)、各有差別的實(shí)際，深入農(nóng)村市場去傾聽農(nóng)民的呼聲和需求，針對性地設(shè)計(jì)、開發(fā)、生產(chǎn)適合農(nóng)村、農(nóng)業(yè)和農(nóng)民需求的產(chǎn)品，特別要注重產(chǎn)品質(zhì)量，結(jié)合農(nóng)村生產(chǎn)生活實(shí)際，才能更好地開拓農(nóng)村市場。

History of past illness

Tumor indicators revealed that the carcinoembryonic antigen was elevated at 3.92 μg/L and carbohydrate antigen 15-3 was elevated at 22.30 kU/L. The thyroid function analysis revealed mild hypothyroidism, with a thyroid stimulating hormone level of 5.61 mU/L and a free thyroxine level of 11.62 pmol/L. Blood analysis and inflammatory indicators were normal.

Personal and family history

The patient had no personal or familial risk factors for thyroid malignancies.

表2給出了對碟式太陽能熱發(fā)電系統(tǒng)進(jìn)行能量分析和 分析的結(jié)果。從表2可以看出最大的能量損耗發(fā)生在斯特林發(fā)電機(jī)，為42.27 kW，其次是集熱子系統(tǒng)，為19.38 kW。集熱子系統(tǒng)熱效率為77.87%，整個碟式太陽能熱發(fā)電系統(tǒng)的熱效率是29.67%。對碟式太陽能熱發(fā)電系統(tǒng) 分析的結(jié)果顯示，集熱子系統(tǒng)的 損失為33.14 kW，斯特林發(fā)電機(jī) 損失為22.44 kW。集熱子系統(tǒng)的 效率為59.37%。碟式太陽能熱發(fā)電系統(tǒng)的整體 效率31.88%。

Physical examination

On physical examination, a hard fixed palpable nontender left lateral neck mass and enlarged thyroid gland were palpated.

Laboratory examinations

The patient had no history of any previous disease.

Imaging examinations

Multimodality ultrasound was performed to evaluate neck swelling, revealing homogeneous enlargement of the thyroid gland without nodules (measuring 2.5 cm ×5.0 cm × 2.2 cm in the right lobe, 2.5 cm x 5.0 cm x 2.0 cm in the left lobe, and 0.8 cm in the isthmus) and level II-VI left abnormally enlarged cervical lymph nodes (the largest measuring 2.7 cm x 2.8 cm x 2.3 cm with microcalcifications and heterogeneous high enhancement (Figure 2A). Fine-needle aspiration cytology (FNAC) of the enlarged thyroid and lymph nodes was conducted for diagnosis (Figure 2B).

Differential diagnosis

Hashimoto’s thyroiditis, Grave’s disease and primary/secondary thyroid malignancy were our initial differential diagnoses to explain the rapid growth of the thyroid gland.

FINAL DIAGNOSIS

The patient was ultimately diagnosed with TM from primary breast cancer and SMs to the contralateral cervical lymph nodes (Figure 3).

通過式(5)可知：當(dāng)β接近1(振幅相等)，α接近π(相位相反)時，對初級聲源而言，就可以在一定的空間區(qū)域得到很大的聲衰減.根據(jù)PAT算法所設(shè)計(jì)的主動消聲系統(tǒng)如圖5所示，主動消聲控制流程如圖6所示.

TREATMENT

Given the suspected bone metastasis and financial issues, the patient was discharged on the NP (vinorelbine and cisplatin) regimen (Figure 1).

OUTCOME AND FOLLOW-UP

To date, after 6 cycles of chemotherapy, the patient has remained clinically stable, and no recurrence at other sites has been detected or confirmed.

DISCUSSION

We performed a comprehensive literature search of the PubMed and Medline databases to identify studies of TM metastasis from breast cancer published from 2000 to 2020, and twenty-five articles were found. Detailed information about thyroid metastatic breast cancer was extracted from these articles (Table 1), and only descriptive analyses and literature reviews were found, given the low incidence of TM.

Metastasis to the thyroid gland is rare due to its rich blood supply; however, reports of TM have increased in recent years as a result of more sophisticated diagnostic methods, such as FNAC and proton emission tomography[5,6]. The characteristics of TM from breast cancer are listed in Table 1. We collected information regarding age,sex, histology of the primary tumor, other sites of recurrence, the time interval between primary diagnosis and TM, presentation of TM, treatment of metastasis,response to the treatment and follow-up for 45 women with TM of breast cancer from 2000 to 2020[6-30]. The development of TM does not seem to be age-related and mostly occurs in women. The time interval between primary and metastatic disease and theprognosis of TM varies among the reports. In two patients, TMs were detected synchronously with the diagnosis of the primary cancer[17,21].

Grade B (Very good): 0

Thyroid metastasis usually occurs in patients with widespread metastatic disease,and the other sites of metastasis are primarily the bone and lung, according to the data shown in Table 1. Not all previously published studies contained information on other recurrence sites, and in 18 patients (41.9%, Table 1), the thyroid was the first and only site of recurrence. In the studies that contained histological information, primary breast cancer was mostly referred to as "invasive" carcinoma (85.7%), indicating that invasive carcinoma might be the most prevalent type of cancer to result in TM(Table 1). Among those reports, two patients had poorly differentiated adenocarcinoma as the primary disease[11], one patient had medullary carcinoma[11], one had metaplastic carcinoma[23], and one had mucinous carcinoma[7].

Patients with TMs generally have a poor prognosis[31,32]. Therapeutic choices for TM vary among reports, depending on the primary cancer origin, recurrence at other sites and the symptoms caused by TM. Surgical excision is considered the first choice for thyroid metastasis, and it has been reported that thyroidectomy improves the prognosis of patients[33]. Patients with multisite metastases are usually recommended for treatment with chemotherapeutic and endocrine approaches according to studies of metastatic breast cancer, but research on the effects of chemotherapy for thyroid metastasis is limited[34]. Among 30 patients, 16 were treated with chemotherapy, and 75% of them were clinically stable during follow-up (Table 1). It is believed that the biological behavior of primary cancer might be the primary influence on the prognosis of patients with TM[2]. Thus, therapeutic choices for TM patients should be determined individually and with multidisciplinary board discussion.

Another notable fact in this case report is that the patient had SMs in the contralateral cervical area of the primary tumor site, and no malignancy was previously found in the left breast or axillary region. SM to the lymph nodes in breast cancer is an important phenomenon, and it is critical to make the correct choice of surgical resection techniques and chemotherapies. It has been reported that only 6% of SMs occur on the contralateral side of the primary tumor site[4], with SMs accounting for 3.5% to 34.6% of metastatic lymph nodes[4,35,36]. Enlarged lymph nodes were detected before diffuse goiter. Aron[37] reported that the vast majority of metastases are able to remain dormant for a long period of time, referred to as metastatic dormancy. This suggests that thyroid metastasis probably occurred before the cervical lymph node changes and remained indolent and silent for a long period of time. It remains unknown whether the metastasis to the contralateral cervical lymph nodes originated from the thyroid metastasis or from the breast directly.

In April 2019, the patient presented at the clinic with a cervical mass and intermittent neck discomfort without pain and airway pressure symptoms. CT revealed lymphadenopathy in the left cervical area and posterior mediastinum.Observation and follow-up were recommended. Two months later, the size of the mass had increased. Further investigation was performed by ultrasound, and levels IV and V left cervical nodal disease was confirmed. On CT with contrast, the patient was found to have left cervical and posterior mediastinum lymph node enlargement and suspected right scapula metastasis. No treatment was initiated per the patient’s decision, and she was scheduled to return to the clinic in 3 mo. In October 2019, the patient presented at her outpatient visit with progressive neck swelling that had persisted for 3 mo.

一架架飛機(jī)從飛雄機(jī)場騰空而起，沿不同的航線飛向全國各地；一輛輛汽車在高速公路上飛馳，讓人們感嘆天塹變通途的快捷；一列列火車在高山峽谷中穿行，描繪著“大進(jìn)大出、暢通無阻”的樞紐宏圖；一條條水泥路連通村村寨寨，承載著決勝脫貧攻堅(jiān)、同步全面小康的期盼；交通的變化，是畢節(jié)最大的變化。交通的發(fā)展，是畢節(jié)發(fā)展的最佳證明。

CONCLUSION

Few studies on diffuse goiter without thyroid nodules and SMs in the contralateral cervical area have been published. This report illustrates that rapidly occurring diffuse goiter without thyroid nodules may be the first sign of TM and that enlarged lymph nodes in the contralateral cervical area may indicate SMs of primary breast cancer.This finding raises awareness of these clinical presentations, which would be helpful for the early detection of metastatic breast cancer. In addition, IHC profiles may change during the process of metastasis, which indicates that biomarker testing for metastatic disease may be crucial for clinical decision-making.